

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims

1-101. (Canceled)

102. (Original) A method for treating a migraine in a subject in need thereof, said method comprising:

administering to said subject a composition comprising a therapeutically effective amount of sumatriptan or a pharmaceutically acceptable salt thereof, a carrier, and a binary buffer system comprising a carbonate salt and a bicarbonate salt, wherein said binary buffer system raises the pH of saliva to a pH greater than about 9.9 irrespective of the starting pH of saliva.

103. (Currently Amended) ~~A method in accordance with~~ The method of claim 102, wherein said composition is a solution composition.

104. (Currently Amended) ~~A method in accordance with~~ The method of claim 103, wherein said binary buffer system comprises sodium bicarbonate and sodium carbonate wherein the ratio of sodium bicarbonate to sodium carbonate is from about 2:1 to about 5:1 by weight, and said composition provides a peak plasma concentration within about 1-15 minutes following administration to said subject.

105. (Original) A method for treating a migraine in a subject in need thereof, said method comprising:

administering to said subject a composition comprising a therapeutically effective amount of a 5-HT agonist or a pharmaceutically acceptable salt thereof, a carrier, and a ternary buffer system comprising a carbonate salt, a bicarbonate salt, and a metal oxide, wherein said ternary buffer system raises the pH of saliva to a pH greater than about 9.9 irrespective of the starting pH of saliva.

106. (Currently Amended) ~~A method~~ The method of claim 105, wherein said ternary buffer system raises the pH of saliva to a pH of from about 9.9 to about 11 irrespective of the starting pH of saliva.

107. (Currently Amended) ~~A method~~ The method of claim 105, wherein said composition delivers said 5-HT agonist across the oral mucosa.

108. (Currently Amended) ~~A method~~ The method of claim 107, wherein said oral mucosa is selected from the group consisting of the sublingual mucosa, the buccal mucosa, and a combination thereof.

109. (Currently Amended) ~~A method~~ The method of claim 105, wherein said migraine is selected from the group consisting of a migraine without aura and a migraine with aura.

110. (Currently Amended) ~~A method~~ The method of claim 105, wherein said 5-HT agonist is selected from the group consisting of sumatriptan, naratriptan, rizatriptan, eletriptan, almotriptan, zolmitriptan, frovatriptan, and combinations thereof.

111. (Currently Amended) ~~A method~~ The method of claim 105, wherein said carbonate salt is selected from the group consisting of sodium carbonate and potassium carbonate.

112. (Currently Amended) ~~A method~~ The method of claim 105, wherein said bicarbonate salt is selected from the group consisting of sodium bicarbonate and potassium bicarbonate.

113. (Currently Amended) ~~A method~~ The method of claim 105, wherein said metal oxide is selected from the group consisting of magnesium oxide and aluminum oxide.

114. (Currently Amended) ~~A method~~ The method of claim 113, wherein said magnesium oxide is amorphous magnesium oxide.

115. (Currently Amended) ~~A method~~ The method of claim 105, wherein said ternary buffer system comprises sodium carbonate, sodium bicarbonate, and amorphous magnesium oxide.
116. (Currently Amended) ~~A method~~ The method of claim 105, wherein said carrier is selected from the group consisting of a binder, a gum base, and combinations thereof.
117. (Currently Amended) ~~A method~~ The method of claim 105, wherein said composition is a dosage form selected from the group consisting of a lozenge, a chewing gum, a chewable tablet, and a dissolving tablet.
118. (Currently Amended) ~~A method~~ The method of claim 117, wherein said dissolving tablet is selected from the group consisting of a slow-dissolving tablet and a quick-dissolving tablet.
119. (Currently Amended) ~~A method~~ The method of claim 105, wherein said oral mucosa is selected from the group consisting of the sublingual mucosa, the buccal mucosa, and a combination thereof.
120. (Currently Amended) ~~A method~~ The method of claim 105, further comprising a 5-HT antagonist.
121. (Currently Amended) ~~A method~~ The method of claim 105, further comprising a non-steroidal anti-inflammatory drug (NSAID).
122. (Currently Amended) ~~A method~~ The method of claim 105, wherein the average particle size of said 5-HT agonist or a pharmaceutically acceptable salt thereof is less than or equal to the average particle size of said carrier.
123. (Currently Amended) ~~A method~~ The method of claim 105, wherein said 5-HT agonist is sumatriptan and said ternary buffer system comprises sodium carbonate, sodium bicarbonate, and amorphous magnesium oxide.

124. (Currently Amended) ~~A method~~ The method of claim 123, wherein said composition is a lozenge or a dissolving tablet.
125. (Currently Amended) ~~A method~~ The method of claim 124, wherein said composition is administered sublingually.
126. (Currently Amended) ~~A method~~ The method of claim 123, wherein the weight percent of amorphous magnesium oxide is greater than the combined weight percent of sodium carbonate and sodium bicarbonate.